Treatment of acrodermatitis continua of hallopeau with ixekizumab

Abstract

Acrodermatitis continua of hallopeau (ACH) is a rare chronic inflammatory variant of pustular psoriasis often restricted to the distal portions the digits in the hands and feet. ACH is of a chronic relapsing nature and is invariably recalcitrant to many available topical and systemic anti-psoriatic therapies. On account of its low prevalence and high resistance to treatments, no clinical guideline of ACH exists. We present a patient with ACH resistant to multiple therapies, including the biologic adalimumab, who was successfully treated with an IL-17 inhibitor (ixekizumab). We believe our unique treatment with an excellent outcome may assist other dermatologists if faced with this condition.

Keywords:

• Acrodermatitis continua of hallopeau
• ixekizumab
• IL-17 biologics

Disclosure statement

Dr. David Cohen discloses that he is speaker/consultant for Eli Lilly and Company Pharmaceuticals for which he has received honorarium. However, this report was not sponsored by Eli Lilly and Company. The other authors have no conflicts of interest to declare.

This work has not been presented prior to this submission.